1989MO Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC): The phase I/II LUPER study

医学 彭布罗利珠单抗 肿瘤科 肺癌 内科学 癌症 免疫疗法
作者
A. Calles Blanco,A.F. Navarro Mendivil,B. Doger de Spéville,E. Colomé,María José de Miguel Luken,Rosa Álvarez,Víctor Moreno,Jorge Ramón,M. Arregui Valles,E. Corral de la Fuente,David Hortigüela Alcalá,Marcelo Sanmartín Fernández,J Morató,Emiliano Calvo,Rosario Sánchez,Maria Jové,Enriqueta Felip
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34: S1060-S1061 被引量:1
标识
DOI:10.1016/j.annonc.2023.09.1220
摘要

Previously, we established the recommended phase 2 dose (RP2D) of LUR + PBL in the phase 1 stage of this study (J Clin Oncol. 2022;40(suppl 16):8581). Here we present the results on the efficacy and safety of the RP2D. LUPER (NCT04358237) is a prospective, open-label, uncontrolled, multicenter, phase 1/2 study of LUR in combination with PBL in patients (pts) with relapsed SCLC. Eligible pts were ≥18 years old, with histologically confirmed SCLC, progression after 1L platinum-based chemotherapy, no prior exposure to immunotherapy, ECOG PS of 0-1, and measurable disease as per RECIST 1.1. Pts with treated, asymptomatic, stable brain metastases (BM) were also included. Treatment consisted of LUR dosed at 3.2 mg/m2 IV Q3W in combination with PBL 200 mg IV Q3W until disease progression (PD), unacceptable toxicity, or consent withdrawal. The primary endpoint was confirmed overall response rate (ORR) according to RECIST 1.1. Secondary endpoints included investigator-assessed Duration of Response (DoR), Progression-Free Survival (PFS), Overall Survival (OS), and safety as per CTCAE 5.0. A total of 28 pts were included in the study. Median age was 65 years (range 41-78), 46.4% were female, 64.3% had ECOG PS of 1, 51.9% had platinum-free interval < 90 days, 39.3% had LDH > upper normal limit, and 21.4% had BM. At data cutoff (March 31, 2023),11 (39.3%) pts were still on treatment. The median follow-up was 5.7 months (range: 1.0-25.2). Preliminary ORR was 46.4% (95% CI: 29.5–64.2; p<0.001): 2 confirmed CR, 11 PR (9 confirmed) and 4 SD ≥12 weeks. Median DoR was 11.4 months (range: 0-21.2 months), and 2 (7.1%) pts had durable responses > 12 months. Median PFS was 5.3 months (95% CI: 2.7-12.0). Median OS was 11.1 months (95% CI: 6.9-NR). PBL and LUR discontinuation occurred in 3 (10.7%) and 0 pts due to immune-related AE, respectively. The most common grade 3 and 4 treatment-emergent AEs (>20%) were fatigue, neutropenia, nausea and anemia. The LUPER study met its primary endpoint. The combination of LUR + PBL is effective in second-line treatment of SCLC with a manageable safety profile. Further research is warranted to confirm the potential of this combination in SCLC patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小吴完成签到 ,获得积分10
1秒前
lz完成签到,获得积分10
2秒前
乒坛巨人完成签到 ,获得积分10
2秒前
庾摇伽完成签到 ,获得积分10
3秒前
花花糖果完成签到 ,获得积分10
3秒前
美好的碧萱完成签到,获得积分20
3秒前
jify完成签到,获得积分10
4秒前
4秒前
sscss完成签到,获得积分10
6秒前
MS903完成签到 ,获得积分10
6秒前
...完成签到 ,获得积分0
7秒前
一氧化二氢完成签到,获得积分10
7秒前
可靠月亮完成签到,获得积分10
7秒前
泉竹晓筱完成签到,获得积分10
7秒前
qinqiny完成签到 ,获得积分10
9秒前
dl发布了新的文献求助10
9秒前
H1lb2rt完成签到 ,获得积分10
9秒前
蕉鲁诺蕉巴纳完成签到,获得积分0
10秒前
留白完成签到 ,获得积分10
10秒前
咿呀咿呀哟完成签到,获得积分0
10秒前
安安完成签到,获得积分10
11秒前
Verdant_Official完成签到,获得积分10
12秒前
zyw完成签到,获得积分10
13秒前
alvin完成签到,获得积分10
13秒前
13秒前
晚灯君完成签到 ,获得积分10
14秒前
CJW完成签到 ,获得积分10
14秒前
xc关注了科研通微信公众号
14秒前
体贴的叛逆者完成签到,获得积分10
14秒前
赵怼怼完成签到,获得积分10
14秒前
秀丽焦完成签到 ,获得积分10
14秒前
木康薛完成签到,获得积分10
14秒前
dl完成签到,获得积分10
16秒前
cindy完成签到,获得积分10
16秒前
研友_nPxRRn完成签到,获得积分10
16秒前
科目三应助奇怪的浮川采纳,获得10
17秒前
冰销雪释完成签到,获得积分10
19秒前
小强123完成签到,获得积分10
20秒前
楚寅完成签到 ,获得积分10
21秒前
量子星尘发布了新的文献求助10
22秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 1000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976745
求助须知:如何正确求助?哪些是违规求助? 3520831
关于积分的说明 11204951
捐赠科研通 3257684
什么是DOI,文献DOI怎么找? 1798834
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806663